Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B

Journal of Clinical Gastroenterology

Volumn 45, Issue 4, 2011, Pages 361-365

  Park, Seung Ha ^a   Kim, Chang Hoon ⁱ   Kim, Dong Joon ^d   Suk, Ki Tae ^d   Cheong, Jae Youn ^e   Cho, Sung Won ^e   Hwang, Seong Gyu ^g   Lee, Youn Jae ^b   Cho, Mong ^c   Yang, Jin Mo ^h   Kim, Young Bae ^f  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Hallym University College of Medicine   (South Korea)

^e Department of Gastroenterology ^*  (South Korea)

^f Ajou University School of Medicine   (South Korea)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h CHA University   (South Korea)

ⁱ STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

biomarker; chronic hepatitis B; liver fibrosis

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; GELATINASE A; HAPTOGLOBIN; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 79952815252     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31820d3458     Document Type: Article

References (25)

1. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C Hepatology. 2003;38:1449-1457. (Pubitemid 37466971)
2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670-1681. (Pubitemid 351615414)
3. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006;43:S113-S120.
4. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44-48. (Pubitemid 29065511)
5. Park GJ, Lin BP, Ngu MC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. 2000;15:386-390. (Pubitemid 30262205)
6. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997;4:199-208. (Pubitemid 127733511)
7. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001; 96:3142-3146. (Pubitemid 33095354)
8. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075. (Pubitemid 32322537)
9. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873. (Pubitemid 41368177)
10. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastro-enterology. 2004;127:1704-1713. (Pubitemid 39575849)
11. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasivemodel. Hepatology. 2005;42:1437-1445.
12. van Weel C, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-918. (Pubitemid 29126890)
13. Guechot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem. 1996;42:558-563. (Pubitemid 26111874)
14. Rossi E, Adams L, Prins A, et al. Validation of the Fibro Test biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49:450-454. (Pubitemid 36250205)
15. Walsh KM, Timms P, Campbell S, et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999;44:624-630. (Pubitemid 29137977)
16. McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology: Consensus Interferon Study Group. J Gastroenterol Hepatol. 2000;15:945-951.
17. Gabrielli GB, Capra F, Casaril M, et al. Serum laminin and type III procollagen in chronic hepatitis C: diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta. 1997;265:21-31. (Pubitemid 27414375)
18. Boeker KH, Haberkorn CI, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C Clin Chim Acta. 2002;316:71-81. (Pubitemid 34028190)
19. Iredale JP, Goddard S, Murphy G, et al. Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond). 1995;89:75-81.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293. (Pubitemid 26260021)
21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843. (Pubitemid 13033817)
22. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890. (Pubitemid 38657490)
23. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222-230. (Pubitemid 36920558)
24. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (Fibro Test-Acti Test) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1970-1980.
25. Parkes J, Guha IN, Roderick P, et al. Performance of serum marker panels for liver fibrosis in chronic hepatitis C J Hepatol. 2006;44:462-474. (Pubitemid 43227870)